Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No pharmacokinetic data located for Prostamax in PubMed/PMC.
No in-vivo dosing regimen found. Only an in-vitro/organotypic effective concentration of 0.05 ng/mL is reported, not convertible to a human dose.
No human dosing/clinical trial located. Evidence is (1) an ex-vivo human-lymphocyte chromatin study (small elderly-donor numbers, cells exposed in vitro) and (2) a rat organotypic prostate-tissue-culture study, both Khavinson-lineage, no independent replication. PubChem has no entry matching this exact tetrapeptide, so MW is left null rather than guessed.
No human in-vivo safety/toxicology data exist. Chromatin/chromosome studies describe genomic-level effects (altered sister-chromatid exchange, NOR activity) interpreted by the authors as beneficial, but such markers are also examined in genotoxicity assessment; no independent genotoxicity/safety evaluation was found. Absence of reported harm is not evidence of safety.
- The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ · pubmed
- Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) · pubmed
- [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats] · pubmed